
Shineco, Inc. Long-Term Debt 2011-2026 | TYHT
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Shineco, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 402 K | - | - | - | 3.86 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.86 M | 402 K | 2.13 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioLineRx Ltd.
BLRX
|
2.74 M | $ 2.25 | 1.81 % | $ 908 M | ||
|
BioNTech SE
BNTX
|
231 M | $ 91.28 | 0.11 % | $ 27.2 B | ||
|
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
1.01 B | $ 330.34 | 3.6 % | $ 43.3 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
22.3 K | $ 0.44 | -16.64 % | $ 5.04 M | ||
|
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
173 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
2.35 M | $ 24.98 | 1.17 % | $ 3.05 B | ||
|
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
1.63 M | $ 10.14 | -0.29 % | $ 135 M | ||
|
Cardiff Oncology
CRDF
|
102 K | $ 1.58 | - | $ 106 M | ||
|
Curis
CRIS
|
428 K | $ 0.53 | -3.07 % | $ 6.98 M | ||
|
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K | ||
|
Crinetics Pharmaceuticals
CRNX
|
42.1 M | $ 37.7 | 1.26 % | $ 3.55 B | ||
|
CRISPR Therapeutics AG
CRSP
|
188 M | $ 49.15 | -0.73 % | $ 4.42 B | ||
|
Adverum Biotechnologies
ADVM
|
86 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
8.14 M | - | -9.65 % | $ 45.9 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
332 | $ 2.96 | -1.0 % | $ 252 M | ||
|
Applied Molecular Transport
AMTI
|
49 K | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
2.95 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | ||
|
CytomX Therapeutics
CTMX
|
4.24 M | $ 4.4 | -3.51 % | $ 607 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - | ||
|
Citius Pharmaceuticals
CTXR
|
21.3 K | $ 0.86 | 0.67 % | $ 5.79 M | ||
|
Cue Biopharma
CUE
|
2.29 M | $ 0.18 | -1.61 % | $ 17.1 M | ||
|
Allena Pharmaceuticals
ALNA
|
210 K | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
69 K | - | 10.36 % | $ 9.8 M | ||
|
Aquestive Therapeutics
AQST
|
45 M | $ 4.09 | -0.97 % | $ 437 M | ||
|
Daré Bioscience
DARE
|
559 K | $ 1.81 | 4.02 % | $ 20.2 M | ||
|
DBV Technologies S.A.
DBVT
|
5.41 M | $ 20.36 | -3.32 % | $ 2.84 B | ||
|
Aravive
ARAV
|
1.88 M | - | -13.39 % | $ 1.45 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
20.8 M | $ 8.22 | 2.37 % | $ 225 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
22.1 M | - | -39.0 % | $ 4.57 M | ||
|
Denali Therapeutics
DNLI
|
5.62 M | $ 19.38 | -6.15 % | $ 3.19 B | ||
|
Dyadic International
DYAI
|
34.6 K | $ 0.87 | -2.8 % | $ 31.5 M | ||
|
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
17.5 B | - | - | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
784 K | $ 31.37 | 1.0 % | $ 2.08 B | ||
|
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M |